| Diagnostic Pharma Equipment | Distribution of diagnostic analyzers and consumables, mainly Abbott's i-STAT products. | Exclusive distribution rights for Abbott's i-STAT analyzers in India; established supplier relationships. | Hospitals, ICU/ICCUs, diagnostic labs (B2B). | Consumable cartridges have higher margins than equipment. | 32 | 97 | Sales of equipment and cartridges to hospitals and diagnostic centers. | Direct sales with volume-based consumable cartridge sales. | Exclusive imports increasing equipment and cartridge sales; rising healthcare diagnostics demand. | i-STAT 1 Analyzer |
| Trading in Securities | Trading and investment in equity shares. | | Company's own equity portfolio activities. | | 0 | 0 | Gains from buying and selling equities. | Market-driven trading. | Market conditions and investment strategies. | |
| Laboratory Testing | Clinical laboratory and diagnostic testing services. | New entrant with backing of parent company and growing presence in major cities. | Healthcare providers and patients (B2B and B2C). | High-complexity diagnostic tests. | 1 | 3 | Fees from diagnostic tests. | Fee-for-service with potential package deals. | Growing diagnostics demand and new lab network expansions. | Clinigenome India Private Limited |
